Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

COMM CONVO: FLUENT IN FINANCE, SCIENCE, AND STRATEGY

Communicators are the ticket into an organization. Through press releases, executive platforms, media access, and the corporate narrative itself, corporate affairs professionals hold the keys to how an organization is seen, understood, and trusted across every function and stakeholder group, both internal and external. Building that fluency in finance, science, and commercial strategy takes deliberate effort, and few organizations have a clear path for how it actually happens. This Comm Convo opens a candid exchange grounded in real experience: how communicators go deep into other functions, learn to speak every stakeholder's language, and meet them on their level and what changes in their work when they do.

Naina Bhasin, Ph.D., Chief Operating Officer, Lifordi Immunotherapeutics

 brings to Lifordi 20 years of life science experience in corporate and business development, strategic planning, and operations. Dr. Bhasin’s broad understanding of the needs of emerging companies has led to a successful track record in building teams, functions, and organizations.

Most recently, Dr. Bhasin served as Chief Business Officer at Ensoma where she was instrumental in building the company from seed stage through Series B. Previously, Dr. Bhasin worked at Intellia Therapeutics as the Chief of Staff to the CEO, leading the planning and execution of a wide variety of strategic initiatives across the business. Prior to that, Dr. Bhasin was Director of Business Development at Shire where she was responsible for the identification, evaluation, and execution of transactions that supported the company’s rare disease strategy. Earlier in her career, she held business development and operational roles at SciFluor Life Sciences, CellzDirect and The Hamner Institutes, a nonprofit research organization.

Dr. Bhasin is a member of the Healthcare Businesswomen’s Association, previously serving as a board member of the Boston Chapter and has been involved with MassBio’s MassCONNECT program. Dr. Bhasin holds a Ph.D. in Cell and Developmental Biology from The University of North Carolina at Chapel Hill and a B.S. in Cell and Structural Biology from the University of Illinois at Urbana-Champaign.

Chris Patil, Ph.D., Vice President, Media, BioAge Labs

 is Vice President of Media at BioAge, a clinical-stage biotech developing medicines that target the biology of aging to treat metabolic disease. He leads public relations and external communications and produces the Translating Aging podcast. Chris built his knowledge of aging biology over two decades as a researcher at UCSF, Berkeley, the Buck Institute, and the Broad Institute, then spent ten years as a scientific editor helping researchers worldwide sharpen their work for publication. That arc — scientist, editor, communicator — shapes how he bridges science, strategy, and storytelling at BioAge, and how he partners with colleagues across finance, clinical, and the executive team. He is also focused on using AI to accelerate and augment human work across the enterprise. He holds a BS in Biological Sciences from Stanford and a PhD in Biochemistry from UCSF.

Peggy Vorwald, Executive Director, IR and Corporate Communications, Caribou Biosciences (Moderator)

T2B June Comm Convo: Fluent in Finance, Science, and Strategy